Medicus Pharma Ltd.
MDCX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.36% | 62.88% | 62.42% | 1,051.82% | 937.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.06% | 143.50% | 138.09% | 1,011.56% | 716.52% |
| Operating Income | -82.06% | -143.50% | -138.09% | -1,011.56% | -716.52% |
| Income Before Tax | -70.54% | -113.65% | -98.96% | -127.26% | -475.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.54% | -113.65% | -98.96% | -127.26% | -475.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.54% | -113.65% | -98.96% | -127.26% | -475.45% |
| EBIT | -82.06% | -143.50% | -138.09% | -1,011.56% | -716.52% |
| EBITDA | -0.37% | -402.80% | -- | -- | -- |
| EPS Basic | 40.68% | 34.88% | 45.79% | 47.23% | -156.92% |
| Normalized Basic EPS | 39.81% | 33.82% | 44.93% | 55.30% | -87.21% |
| EPS Diluted | 22.37% | 14.95% | 45.79% | 47.23% | -156.92% |
| Normalized Diluted EPS | 39.81% | 33.82% | 44.93% | 55.30% | -87.21% |
| Average Basic Shares Outstanding | 79.62% | 105.33% | 166.77% | 341.57% | 250.04% |
| Average Diluted Shares Outstanding | 79.62% | 105.33% | 166.77% | 341.57% | 250.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |